Now on
Orphan Drug Designation to sirolimus in Sickle Cell Disease
Orphan Drug Designation to sirolimus in Sickle Cell Disease
Orphan Drug Designation for the use of Teicoplanin in Cystic Fibrosis
The European Commission grants Orphan Drug Designation to Neupharma for the use of Teicoplanin in Cystic Fibrosis, a program developed in collaboration with Rare Partners
Rare Partners supports the Istituto Italiano di Tecnologia (IIT) for the development of an innovative artificial retina
Rare Partners supports the IIT for the development of an innovative artificial retina
A new Orphan Drug Designation to Sirolimus
A new Orphan Drug Designation to Sirolimus
Rare Partners presents a poster on Thalassemia project
Rare Partners presents a poster on Thalassemia project.